Meeting
2020 ASCO Virtual Scientific Program
ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer.
Authors
Jon Holmlund
Galera Therapeutics, Malvern, PA
Jon Holmlund , Jeffrey Mark Brill , Robert Fairbanks , Deborah Saunders , Stephen T. Sonis , Matt Downs , Carryn M. Anderson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03689712
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS6596)
DOI
10.1200/JCO.2020.38.15_suppl.TPS6596
Abstract #
TPS6596
Poster Bd #
257
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer.
First Author: Daniel Osei-Fofie
Poster
2022 ASCO Annual Meeting
Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer.
First Author: Christina Henson
Poster
2022 ASCO Annual Meeting
Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in patients with head and neck cancer treated with chemoradiation (PREVLAR).
First Author: Marcelo Raul Bonomi
Poster
2016 ASCO Annual Meeting
Randomized phase II trial (RENO): efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC). SLCG 10/02.
First Author: Mariano Provencio